What are the clinical features, diagnostic work‑up, and management of Friedreich’s ataxia?

Friedreich's Ataxia: Clinical Features, Diagnosis, and Management

Clinical Features

Friedreich's ataxia (FRDA) is an autosomal recessive neurodegenerative disorder characterized by progressive ataxia, cardiomyopathy, and skeletal deformities, with typical onset around puberty and shortened lifespan often due to cardiac complications 1.

Core Neurological Features

• Progressive gait and limb ataxia with poor balance and coordination
• Sensory loss affecting vibration sense and proprioception (positive Romberg test)
• Areflexia in lower limbs with pyramidal weakness
• Dysarthria and dysphagia due to bulbar involvement
• Eye movement abnormalities including nystagmus and dysmetria
• Truncal ataxia reflecting cerebellar vermian pathology 2, 1

Non-Neurological Manifestations

• Hypertrophic cardiomyopathy (major cause of mortality)
• Scoliosis and pes cavus (foot deformities)
• Diabetes mellitus and glucose metabolism disturbances
• Spinal cord and dorsal root ganglia atrophy
• Dentate nucleus atrophy without global cerebellar volume reduction 3

Atypical Phenotypes

Late-onset cases (>25 years) tend to have:

• Slower disease progression
• Smaller GAA expansions
• Retained reflexes in some cases
• Lower frequency of cardiomyopathy and diabetes 1

Early-onset cases show:

• More rapid progression
• Higher frequency of scoliosis, pes cavus, and cardiomyopathy
• Larger GAA expansions 1

---

Diagnostic Work-Up

Genetic Testing: The Diagnostic Gold Standard

DNA analysis for GAA triplet repeat expansion in the frataxin gene (FXN) on chromosome 9q13 is the definitive diagnostic test 3. The vast majority of cases (>95%) show biallelic unstable intronic GAA expansions. A small subset are compound heterozygotes with one GAA expansion and one point mutation or deletion 1.

When to Suspect FRDA

Consider FRDA in patients with:

• Progressive ataxia with onset typically between ages 5-25 years
• Absent lower limb reflexes with extensor plantar responses (unique combination)
• Cardiomyopathy in a young patient with ataxia
• Family history suggesting autosomal recessive inheritance (particularly in consanguineous families)

Stepwise Diagnostic Algorithm for Chronic Progressive Ataxia

For patients presenting with chronic progressive ataxia:

1. Rule out acquired causes first (structural lesions, toxins, nutritional deficiencies, immune-mediated)

2. If family history suggests recessive inheritance:

   • First-line: Friedreich's ataxia genetic testing (GAA expansion analysis)
   • If negative, proceed to biochemical markers and targeted genetic testing for:
     • Ataxia telangiectasia
     • Ataxia due to vitamin E deficiency
     • POLG gene mutations
     • ARSACS (autosomal recessive spastic ataxia of Charlevoix-Saguenay)
     • AOA types 1 and 2 4

3. If family history is negative but onset <45 years:

   • Screen for common dominant ataxias (SCA 1,2,3,6,7,17)
   • Still perform full recessive ataxia work-up including FRDA 4

4. If sporadic with onset >30 years:

   • Consider multiple system atrophy
   • Screen for FMR1 premutations if onset >45 years 4

Neuroimaging

MRI head without IV contrast is the preferred initial imaging modality for chronic ataxia 5. MRI is superior to CT for detecting:

• Cerebellar and brainstem atrophy
• Spinal cord atrophy (particularly cervical cord)
• Dentate nucleus changes
• Patterns of parenchymal injury suggesting specific ataxia subtypes

Key imaging findings in FRDA:

• Spinal cord atrophy (especially cervical)
• Dentate nucleus atrophy
• Preserved cerebellar cortex (unlike many other ataxias)
• No significant supratentorial abnormalities 3

Important caveat: Conventional neuroimaging may be unremarkable in early FRDA, so normal MRI does not exclude the diagnosis 5.

Cardiac Evaluation

• Baseline ECG and echocardiogram are mandatory at diagnosis
• Serial cardiac monitoring is essential as cardiomyopathy is the leading cause of death 6

---

Management

Disease-Modifying Therapy

Omaveloxolone is the only FDA-approved disease-modifying therapy for FRDA, showing statistically significant improvement in modified Friedreich Ataxia Rating Scale (mFARS) scores 7. This Nrf2 activator demonstrated a mean difference of -2.40 points (95% CI -4.24 to -0.56; p=0.014) compared to placebo, though this rests on low-certainty evidence 7.

Critical point: Omaveloxolone represents the most promising pharmacological intervention currently available, making early recognition and diagnosis of FRDA essential for timely treatment initiation 8, 9.

Symptomatic Pharmacological Management

While most pharmacological trials have yielded inconsistent results 7:

• Riluzole (level B evidence): May provide symptomatic relief regardless of etiology 4
• Amantadine (level C evidence): Might offer symptomatic benefit 4
• Idebenone is NOT effective in FRDA (level A evidence) 4

Non-Pharmacological Interventions

Non-pharmacological therapies yield more consistent patient-relevant gains than most pharmacological interventions 9:

• Physiotherapy (level II evidence): Recommended for all patients 4
• Occupational therapy (level III evidence): Supports functional independence 4
• Cardiac interventions: Essential for managing cardiomyopathy
• Rehabilitation programs: Show consistent functional improvements 9

Multidisciplinary Care Requirements

Given the multisystemic nature of FRDA, coordinate care across:

• Neurology: Disease monitoring and symptomatic management
• Cardiology: Serial echocardiograms, arrhythmia management, heart failure treatment
• Orthopedics: Scoliosis monitoring and surgical intervention when indicated
• Endocrinology: Diabetes screening and management
• Physical/occupational therapy: Ongoing functional support
• Speech therapy: For dysarthria and dysphagia 6

Monitoring and Prognosis

• Disease progression is typically slow but relentless
• Average time from onset to death is 36 years 10
• Cardiac complications are the leading cause of mortality
• Smaller GAA expansions correlate with later onset and slower progression 1

---

Critical Gaps in Current Evidence

Important limitation: Most pharmacological studies show biological improvements without clear clinical benefit, whereas rehabilitation and cardiac interventions demonstrate more tangible patient outcomes 9. The field urgently needs:

• Larger, longer-duration randomized controlled trials
• Standardized outcome measures
• Patient- and caregiver-reported outcomes
• Studies addressing mental health and caregiver burden (currently <2% of research) 9

Common pitfall: Do not delay genetic testing while pursuing extensive imaging or other investigations. DNA analysis is definitive and should be performed early when FRDA is suspected clinically.